BRCA1 and BRCA2 mutations account for most families with hereditary breast and ovarian cancer syndrome (HBOC),1 and the estimated lifetime risk of breast cancer in women with BRCA1 mutations is 50% to 80%; for BRCA2, the risk is 40% to 70%.2
At Integrated Genetics, we understand the importance of identifying patients with a BRCA mutation. With the analytical sensitivity and specificity of Integrated Genetics’ BRCAssure assay, and a comprehensive suite of tests to identify BRCA mutations associated with breast and ovarian cancer, you can have confidence in the test performance and select the BRCAssure testing option that is the most appropriate for your patient based on her or his personal or family medical history.
BRCA estimated lifetime cancer risk chart
Helping patients understand their results
Discussing BRCAssure testing results with patients can be a challenge in the short time you have to speak with them during an appointment. To help simplify the discussion, Integrated Genetics is pleased to provide you with patient reports for our BRCAssure Comprehensive and BRCAssure Ashkenazi Jewish tests. Each report provides information on the test result and the possible next steps, if any, the patient should consider, including speaking with a genetic counselor.
Full sequencing of the BRCA1/2 genes, plus deletion/duplication analysis. May be used to assess the risk of carrying a BRCA1/2 mutation when the patient’s history suggests an increased risk for hereditary breast and ovarian cancer in the absence of a known familial mutation. Learn more
BRCAssure—Ashkenazi Jewish panel
Targeted analysis of the founder mutations found within the Ashkenazi Jewish population. May be used as a first line test for individuals of Ashkenazi Jewish descent; if negative the option to run a Comprehensive BRCA1/2 Analysis is available. Learn more
BRCAssure—BRCA1/2 deletion/duplication analysis
May be used to detect the presence of a deletion or duplication in the BRCA1/2 genes after previous sequencing tests were negative and deletion/duplication analysis was not offered or when a specific familial duplication or deletion is known. Learn more
Other testing options
In addition to hereditary cancer screening, we also offer: serum screening and noninvasive prenatal testing (NIPT, sometimes called NIPS or cell-free DNA), including the pioneering whole-genome NIPT; carrier screening, from comprehensive to single-gene; and diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples.
- American College of Obstetricians and Gynecologists. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. Obstet Gynecol. April 2009; 113:957-66. Reaffirmed 2013.
- Petrucelli N, Daly MB and Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. GeneReviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1247. Published September 4, 1998. Updated September 26, 2013. Accessed October 22, 2013.